Letter to the Editor

Pharmacoeconomic Aspects of Treating Hemorrhoidal Disease - Cost of Illness Study Based on Data from Balkan Country with Recent History of Social and Economic Transition

1. Anderson P, Dalziel K, Davies E, et al (2014). Survey of digestive health across Europe: Final report. Part 2: The economic impact and burden of digestive disorders. United European Gastroenterol J, 2(6):544-6.
2. Sandler RS, Everhart JE, Donowitz M, et al (2002). The burden of selected digestive diseases in the United States. Gastroenterology, 122(5):1500-11.
3. Dik VK, Siersema PD, Joseph A, et al (2014). Constipation-related direct medi-cal costs in 16 887 patients newly diag-nosed with chronic constipation. Eur J Gastroenterol Hepatol, 26(11): 1260-6.
4. Jo C (2014). Cost-of-illness studies: con-cepts, scopes, and methods. Clin Mol Hepatol, 20(4):327-37.
5. Janković SM, Kostić M, Radosavljević M, et al (2009). Cost-effectiveness of four im-munomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on data a Balkan country in socioeconomic transition. Vojnosanit Pregl. 2009;66(7):556-62.
Files
IssueVol 50 No 6 (2021) QRcode
SectionLetter to the Editor
Published2021-06-10

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Božović B, Radoičić M, Janković S, Anđelković J, Kostić M. Pharmacoeconomic Aspects of Treating Hemorrhoidal Disease - Cost of Illness Study Based on Data from Balkan Country with Recent History of Social and Economic Transition. Iran J Public Health. 50(6):1288-1290.